Evaluation of alpelisib-induced hyperglycemia prophylaxis and associated risk factors in PIK3CA-mutated hormone-receptor positive, human epidermal growth factor-2 negative advanced breast cancer

被引：0
|
作者：
Sarah E. Burnette
Emily Poehlein
Hui-Jie Lee
Jeremy Force
Kelly Westbrook
Heather N. Moore
机构：
[1] Atrium Health Wake Forest Baptist,Department of Pharmacy
[2] Duke University,Department of Biostatistics and Bioinformatics
[3] Duke University Cancer Institute,Department of Breast Oncology
[4] Duke University Medical Center,Department of Pharmacy
来源：
Breast Cancer Research and Treatment | 2023年 / 197卷
关键词：
Alpelisib; Metastatic breast cancer; Hormone-receptor positive; PIK3CA; Hyperglycemia; Rash;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：369 / 376
页数：7
相关论文
共 50 条
  • [21] Alpelisib: A Well-Tolerated Treatment Option for Patients with HR-Positive, HER2-Negative PIK3CA-Mutated Advanced Breast Cancer
    Diao, Fei-Yu
    GLOBAL MEDICAL GENETICS, 2022, 09 (01): : 1 - 3
  • [22] Alpelisib (ALP) plus endocrine therapy (ET) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2e) advanced breast cancer (ABC): Subgroup analyses from the BYLieve study
    Cardoso, F.
    Juric, D.
    Lerebours, F.
    Krop, I.
    Borrego, M. Ruiz
    Neven, P.
    Park, Y. H.
    Yardley, D.
    Jhaveri, K.
    Arce, C.
    Gu, E.
    Akdere, M.
    Rugo, H. S.
    ANNALS OF ONCOLOGY, 2022, 33 : S206 - S207
  • [23] Analysis of PIK3CA mutations in the primary and recurrent tumors of hormone receptor positive/human epidermal growth factor receptor 2 negative breast cancer
    Wang, Yue
    Li, Xin
    Zhang, Shuang
    Liang, Li
    Xu, Ling
    Liu, Yinhua
    Li, Ting
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 54 (09) : 1024 - 1031
  • [24] The association between baseline patient characteristics and alpelisib-induced hyperglycaemia in patients with HR+, HER2-, PIK3CA-mutated metastatic breast cancer
    Godina, Eva
    Borstnar, Simona
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [25] Alpelisib (ALP) plus endocrine therapy (ET) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR plus ), human epidermal growth factor-2-negative (HER2-) advanced breast cancer (ABC): First interim BYLieve study results.
    Rugo, Hope S.
    Borrego, Manuel Ruiz
    Chia, Stephen K. L.
    Juric, Dejan
    Turner, Nicholas C.
    Drullinsky, Pamela
    Lerebours, Florence
    Bianchi, Giulia Valeria
    Nienstedt, Carolyn C.
    Ridolfi, Antonia
    Thuerigen, Astrid
    Ciruelos, Eva
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [26] FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer
    Narayan, Preeti
    Prowell, Tatiana M.
    Gao, Jennifer J.
    Fernandes, Laura L.
    Li, Emily
    Jiang, Xiling
    Qiu, Junshan
    Fan, Jianghong
    Song, Pengfei
    Yu, Jingyu
    Zhang, Xinyuan
    King-Kallimanis, Bellinda L.
    Chen, Wei
    Ricks, Tiffany K.
    Gong, Yutao
    Wang, Xing
    Windsor, Katherine
    Rhieu, Steve Y.
    Geiser, Gerlie
    Banerjee, Anamitro
    Chen, Xiaohong
    Turcu, Francisca Reyes
    Chatterjee, Deb K.
    Pathak, Anand
    Seidman, Jeffrey
    Ghosh, Soma
    Philip, Reena
    Goldberg, Kirsten B.
    Kluetz, Paul G.
    Tang, Shenghui
    Amiri-Kordestani, Laleh
    Theoret, Marc R.
    Pazdur, Richard
    Beaver, Julia A.
    CLINICAL CANCER RESEARCH, 2021, 27 (07) : 1842 - 1849
  • [27] ADVERSE EVENT MANAGEMENT DURING TREATMENT WITH ALPELISIB FOR HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE ADVANCED BREAST CANCER
    Colella, Sarah
    Lacouture, Mario
    Farooki, Azeez
    Juric, Dejan
    ONCOLOGY NURSING FORUM, 2018, 45 (02)
  • [28] Alpelisib plus letrozole in patients with PIK3CA-mutated, hormone-receptor positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) previously treated with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + fulvestrant: BYLieve study results
    Rugo, Hope S.
    Lerebours, Florence
    Juric, Dejan
    Turner, Nicholas
    Chia, Stephen
    Drullinsky, Pamela
    Prat, Aleix
    Villanueva Vazquez, Rafael
    Akdere, Murat
    Arce, Christina
    Shen, Yu-Ming
    Ciruelos, Eva
    CANCER RESEARCH, 2021, 81 (04)
  • [29] Patient-reported outcomes (PROs) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2) advanced breast cancer (ABC) from SOLAR-1.
    Mayer, Ingrid A.
    Rugo, Hope S.
    Loibl, Sibylle
    Safra, Tamar
    Park, Yeon Hee
    Krivorotko, Petr
    Iwata, Hiroji
    Andre, Fabrice
    Conte, Pier Franco
    Ciruelos, Eva
    Juric, Dejan
    Park, Jinhee
    Wilke, Celine
    Mills, David
    Lteif, Agnes
    Campone, Mario
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [30] Expert consensus recommendations for managing hyperglycemia and rash in patients with PK3CA-mutated, hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with alpelisib (ALP)
    Gallagher, Emily J.
    Moore, Heather
    Lacouture, Mario E.
    Dent, Susan Faye
    Farooki, Azeez
    Goncalves, Marcus D.
    Isaacs, Claudine
    Johnston, Abigail
    Juric, Dejan
    Quandt, Zoe
    Spring, Laura
    Berman, Brian
    Decker, Melanie
    Hortobagyi, Gabriel N.
    Kaffenberger, Benjamin
    Kwong, Bernice Y.
    Pluard, Timothy J.
    Rao, Ruta D.
    Schwartzberg, Lee S.
    Broder, Michael S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (28) : 422 - 422
12345